<DOC>
	<DOCNO>NCT01887795</DOCNO>
	<brief_summary>1 . Verify effect Erlotinib concurrent whole-brain radiation therapy ﬁrst-line treatment patient multiple brain metastasis non-small-cell lung cancer compare WBRT alone . 2 . Verify pre-built EGFR mutation prediction model NSCLC brain metastasis</brief_summary>
	<brief_title>Phase Ⅲ Trial WBRT Versus Erlotinib Concurrent Whole-brain Radiation Therapy ﬁrst-line Treatment Patients With Multiple Brain Metastases From Non-small-cell Lung Cancer ( ENTER ) : Multicentre , Open-label , Randomised Study</brief_title>
	<detailed_description>All patient randomize receive WBRT Erlotinib concurrent WBRT . Erlotinib concurrent WBRT , patient give load dose erlotinib 150mg per day 6 day , patient receive erlotinib 150mg per day concurrently WBRT . Dose reduction allow intolerable adverse effect ( grade ≥3 ) rash diarrhea 50 mg increment 150mg 100 mg 50 mg need . Radiation therapy deliver 2.0 Gy fraction per day 5 day per week total dose 40Gy ( 20 fraction ) . Radiation deliver opposed lateral 8-MV beam Sweden precise linear accelerator .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>1 . 18 year age old ; 2. pathological diagnosis nonsmall cell lung cancer detection pulmonary primary ARMs / sequence EGFR mutation ; 3. enhance MRI show brain metastasis ≥ 2 NSCLC brain metastasis resection residual lesion ≥ 2 / intracranial metastasis patient new ; 4. previous use EGFRTKIs , WBRT synchronous Erotinib treatment disable EGFRTKIs ≥ 4 week ; 5. expect survival period 2 month ; 6 . KPS score ≥ 70 ; 7 . GPA score 0.5 3.5 ; 8. week randomization , bone marrow liver kidney function patient meet follow criterion : 1 . HB ≥ 100 , g/L ≥ 1.5 × 109/L neutrophil platelet ≥ 100 × 109/L ; 2. total bilirubin ≤ 1.5 time upper limit normal , aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) ≤ 1.5 time upper limit normal ; 3. 1.5 time upper limit normal serum creatinine creatinine clearance rate ≥ 60 ml/min , urea N ≤ 200mg/L ; 4 . Urine dipstick test proteinuria &lt; 1+ ; urine dipstick test value , 1+ , 24 hour total urine protein must &lt; 500mg . 9. compliance research plan followup process , able carry oral therapy ; 10. woman childbearing age , must start treatment within 7 day urine pregnancy test result negative , lactation period , reproductive age men woman prior entry study , research process 90 day stop agree use reliable method contraception ; 11. understand consent . 1. patient treat radiation brain erlotinib ingredient allergy ; 2. mixed small cell lung cancer patient component ; 3 . 5 year cancer except NSCLC treatment patient start study ( except simple operation resection least 5 consecutive year disease free survival , cure cervical carcinoma situ , cure base cell cancer bladder epithelial tumor ) ; 4. enter group 4 week receive investigational drug ; 5. judgment accord researcher , serious harm patient safety affect patient complete study disease , patient compliance difference ; 6. clinical evidence moderate severe chronic obstructive pulmonary disease ( COPD COPD history risk factor pulmonary function testing , FEV1/FVC &lt; 70 % , FEV1 &lt; 80 % estimate , without chronic cough , sputum , difficulty breathing ) , activity interstitial lung disease ( ILD pulmonary function test FEV1/FVC &lt; 70 % , FEV1 &lt; 80 % estimate , dispersion carbon monoxide lung volume DLCO &lt; 40 % , high resolution CT show diffuse interstitial lung disease ) disease activity researcher decide ; 7. gastrointestinal physiology perfect , absorb obstacle syndrome , unable tolerate oral medication , active peptic ulcer ; 8. unstable system disease : include active infection , uncontrolled hypertension , unstable angina pectoris , within last 3 month onset angina , congestive heart failure , group June myocardial infarction , need serious mental disorder drug treatment , liver , kidney metabolic disease ; mental / spiritual diseases Alzheimer 's disease ; 9. without full control ocular inflammation eye infection , may cause eye disease situation ; 10. know human immunodeficiency virus ( HIV ) infection ; 11. immunodeficiency disease , suffer acquire , congenital immunodeficiency disease , history organ transplantation ; 12. disease , metabolic disorder , physical examination laboratory suspicion treatment complication patient high risk drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Informed Consent ;</keyword>
	<keyword>Ethical Principles ;</keyword>
	<keyword>Data collection</keyword>
</DOC>